Our Board of Directors
Vicente Anido, Jr, Ph.D.
Chief Executive Officer and Chairman of the Board
Vicente Anido, Jr., Ph.D. has served as our Chief Executive Officer since July 2013 and as Chairman of our Board since April 2013. Dr. Anido is the former President, Chief Executive Officer, and Director of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012. Prior to joining ISTA Pharmaceuticals, Dr. Anido served as general partner of Windamere Venture Partners from 2000 to 2001. From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996, Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan’s commercial operations for North and South America. Prior to joining Allergan, Dr. Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion’s U.S. Prescription Products Division. Dr. Anido previously served as a member of the board of directors of QLT Inc. from 2012 to 2013, Depomed, Inc. from February 2013 to May 2016, and Nicox S.A. from June 2013 to June 2014. In addition, from 2002 to 2008, Dr. Anido served as a member of the board of directors of Apria Healthcare, Inc. Dr. Anido received his B.S. and M.S. from West Virginia University and his Ph.D. from the University of Missouri, Kansas City.
Gerald D. Cagle, Ph.D.
Former Chief Executive Officer at Cognoptix, Inc., Former SVP, Research and Development, and Chief Scientific Officer at Alcon Laboratories, Inc.
Gerald D. Cagle, Ph.D. has served as a member of our Board since September 2013. Dr. Cagle was appointed Senior Vice President of Research and Development at Alcon Laboratories, Inc. in 1997, a position he held until 2009. From 2009 until his retirement in 2013, Dr. Cagle held the position of Chief Operating Officer at Cognoptix, a company focused on the diagnosis of Alzheimer’s disease. Dr. Cagle also serves on the board of directors of GrayBug, Inc., Clearside Biomedical, Inc., and Novaliq GmbH, and donates time to Foundation Fighting Blindness. He received his B.S. from Wayland College, earned both his M.S. and Ph.D. from the University of North Texas, and completed the Program for Management Development at Harvard Business School.
- Chair of the Nominating and Governance Committee
- Member of the Compensation Committee
Former Senior Vice President, Chief Financial Officer, and Corporate Strategy Officer, Alcon Laboratories, Inc.
Richard Croarkin has served as a member of our Board since May 2015. Mr. Croarkin previously served as Chief Financial Officer of Nestle Health Science, a division of Nestle focused on medicalized nutrition solutions for chronic medical conditions from December 2010 to February 2013. During his tenure, he was responsible for financial strategy in support of the R&D pipeline, including multiple transactions ranging from minority stakes and joint ventures, to outright acquisitions. Prior to this, Mr. Croarkin was Senior Vice President, Chief Financial Officer, and Corporate Strategy Officer at Alcon, which had annual sales of $7.1 billion and was the world’s leading ophthalmic pharmaceutical and medical device company before its acquisition by Novartis for $50 billion. Previously, he was Executive Vice President and Chief Financial Officer of Nestle Waters North America, overseeing the finances of a business unit that grew to $4.4 billion in sales. Before joining Nestle, Mr. Croarkin worked for PepsiCo, Inc., where he served in a number of senior financial positions around the world, including as Chief Financial Officer of Pepsi Latin America and Pepsi Canada. He started his career with AMAX, Inc., where he worked in treasury, corporate development, and planning. Mr. Croarkin was a Director on the Supervisory Board of the German publicly traded company, WaveLight A.G., which manufactures and globally markets laser and diagnostic systems for refractive eye surgery. Mr. Croarkin currently serves as a member of the board of directors of Clearside Biomedical, a company advancing eye disease therapies by delivering drugs to the suprachoroidal space via a proprietary microinjector. He also serves on occasion as a panelist on the NASDAQ Listing Qualifications Panel. Mr. Croarkin received his B.A. degree in economics from Georgetown University and his MBA in finance from the University of Connecticut.
- Member of the Audit Committee
Mechiel (Michael) M. du Toit
Chief Growth Officer at Publicis Health
Mechiel (Michael) M. du Toit has served as a member of our Board since June 2015. In December 2017, Mr. du Toit was appointed Chief Growth Officer of Publicis Health, a division of Publicis Groupe, S.A., the third largest advertising and media company in the world. He previously served as President of Everyday Health since February 2015. Prior to this, Mr. du Toit served in various positions, including Global Group President, at Publicis Healthcare Communications Group from March 2012 to February 2015. He held various senior executive positions from July 2006 to February 2012 at other companies, including President of Digitas Health where he was a founding member, Digitas Health Media, and RazorFish Health. Mr. du Toit also has held executive roles at premier marketing agencies including Grey Advertising, BBDO, and inVentiv Health Communications. He also held senior marketing positions at pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim Pharmaceuticals. At Glaxo, as Vice President of Marketing, he launched several blockbuster pharmaceutical products, including Serevent® (salmeterol) and Flonase® (fluticasone nasal). Mr. du Toit previously served as a member of the National Pharmaceutical Council, Pharmaceutical Advertising Council, Advertising Club of Fairfield, Advertising Club of New York, Editorial Board of Medical Marketing and Media, Prescription Drug Advertising Coalition, and Triangle Advertising Federation. He started his career at Unilever, a consumer products company. He received his B.S. in Economics and Marketing from Stellenbosch University in South Africa.
- Member of the Nominating and Governance Committee
- Member of the Compensation Committee
Murray A. Goldberg
Former Chief Financial Officer at Regeneron Pharmaceuticals, Inc.
Murray A. Goldberg has served as a member of our Board since August 2013. Mr. Goldberg retired from Regeneron Pharmaceuticals, Inc. at the end of 2014, after serving as Senior Vice President, Administration from October 2013 and Assistant Secretary since January 2000. He also served as Chief Financial Officer and Senior Vice President, Finance and Administration from March 1995 to October 2013, and as Treasurer from March 1995 to October 2012. He currently serves on the Board of Directors of Teva Pharmaceutical Industries Ltd. and Ayala Pharmaceuticals, Inc. Prior to joining Regeneron Pharmaceuticals, Inc., Mr. Goldberg was Vice President, Finance, Treasurer, and Chief Financial Officer of PharmaGenics, Inc., a biotechnology company, from February 1991, and a Director of PharmaGenics Inc. from May 1991. From 1987 to 1990, Mr. Goldberg was Managing Director, Structured Finance Group at the Chase Manhattan Bank, N.A., and from 1973 to 1987 he served in various managerial positions in finance and corporate development at American Cyanimid Company, a diversified industrial company. Mr. Goldberg received his M.B.A. from the University of Chicago and a M.Sc. in Economics from the London School of Economics.
- Chair of the Audit Committee
DAVID W. GRYSKA
Former Chief Financial Officer and Executive Vice President at Incyte Corp
David W. Gryska rejoined our Board in September 2018, after serving as a member from May 2012 through May 2015. Mr. Gryska retired from Incyte Corp., where he was Chief Financial Officer and Executive Vice President, at the end of 2018. He currently serves on the Board of Directors of Seattle Genetics, Inc. and PDL BioPharma, Inc. Mr. Gryska has spent over 20 years as a senior executive at life science and biotechnology companies with extensive experience relating to financings, acquisitions, global expansion and strategic transactions. Prior to joining Incyte Corp., he held positions including President, CEO, COO and Director at Myrexis, Inc., Chief Financial Officer and Senior Vice President at Celgene Corp., and Chief Financial Officer and Senior Vice President at Scios, Inc. Mr. Gryska holds a BA in Accounting and Finance from Loyola University in Chicago and an MBA from Golden State University.
- Member of the Audit Committee
Benjamin F. McGraw, III, Pharm.D.
Executive Chairman and Chief Executive Officer at TheraVida, Inc.
Benjamin F. McGraw, III, Pharm.D. has served as a member of our Board since September 2014. Dr. McGraw has served as Executive Chairman and Chief Executive Officer of TheraVida, Inc., a specialty pharmaceutical company, since 2011 and 2013, respectively. He has also served as Chief Executive Officer of Auration Biotech, Inc., a private biotechnology company, since 2014. He currently serves on the Board of Directors of Trefoil, Inc. Dr. McGraw had also served as a Managing Member of Long Shadows Asset Management, LLC, a registered investment advisor. Previously, Dr. McGraw was Chairman, President, and CEO of Valentis, Inc., Corporate Vice President, Corporate Development at Allergan, Inc., and Vice President, Development at Marion Laboratories, Inc. and Marion Merrell Dow, Inc. Dr. McGraw received his B.S. and his Pharm.D. from the University of Tennessee Health Science Center, where he also completed a clinical practice residency.
- Lead Independent Director
- Chair of the Compensation Committee
Chair of the Board at Ironwood
Julie McHugh has served as a member of our Board since June 2015. Ms. McHugh served as Chief Operating Officer of Endo Health Solutions, Inc., from March 2010 until her retirement in May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to this, Ms. McHugh was CEO of Nora Therapeutics, Inc., a venture capital–backed biotech start-up company focused on developing novel therapies for the treatment of infertility disorders. Previously, she served as company group Chairman for Johnson & Johnson’s worldwide virology business unit, and prior to this, she was president of Centocor, Inc., a J&J subsidiary. In this role, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir), and Intelence® (etravirine). Prior to joining Centocor, Ms. McHugh led marketing communications for the gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck, Inc. She currently serves as Chair of the Board of Directors of Ironwood Pharmaceuticals, Inc., and serves on the Board of Directors of Lantheus Holdings, Inc., New Xellia Group A/S, and Trevena Pharmaceuticals, Inc. She previously served on the Board of Directors of the Biotechnology Industry Organization (BIO), the New England Healthcare Institute (NEHI), the Pennsylvania Biotechnology Association, and ViroPharma Inc. Ms. McHugh received her M.B.A. from St. Joseph’s University and her B.S. from Pennsylvania State University.